Tiziana Life Sciences logo

TILS - Tiziana Life Sciences Share Price

134p -8.0  -5.6%

Last Trade - 3:42pm

Small Cap
Market Cap £271.8m
Enterprise Value £272.6m
Revenue £n/a
Position in Universe 667th / 1806
Unlock TILS Revenue
Relative Strength (%)
1m +0.53%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -52.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 15,520 24,431
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Tiziana Life Sciences PLC revenues was not reported. Net loss increased 23% to £7.3M. Higher net loss reflects Operating Expenses increase of 49% to £4.9M (expense), Interest Exp-Net of Capitalized Interest increase from £9K to £49K (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -£0.05.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for TILS
Graphical History


TILS Revenue Unlock TILS Revenue

Net Income

TILS Net Income Unlock TILS Revenue

Normalised EPS

TILS Normalised EPS Unlock TILS Revenue

PE Ratio Range

TILS PE Ratio Range Unlock TILS Revenue

Dividend Yield Range

TILS Dividend Yield Range Unlock TILS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TILS EPS Forecasts Unlock TILS Revenue
Profile Summary

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its lead product candidates include Milciclib (TZLS-201) and Foralumab (TZLS-401). Its products also include Anti IK-6r (TZLS-501) and StemPrintER. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib has completed Phase IIa trials as a monotherapy for the treatment for thymic carcinoma and hepatocellular carcinoma (HCC). The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. Foralumab has completed Phase II trial and has potential application in a wide range of autoimmune and inflammatory diseases.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated February 11, 1998
Public Since May 9, 2000
No. of Shareholders: n/a
No. of Employees: 10
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange London Stock Exchange (AIM)
Shares in Issue 191,441,073
Free Float (0.0%)
Eligible for
TILS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TILS
Upcoming Events for TILS
Frequently Asked Questions for Tiziana Life Sciences
What is the Tiziana Life Sciences share price?

As of 3:42pm, shares in Tiziana Life Sciences are trading at 134p, giving the company a market capitalisation of £271.8m. This share price information is delayed by 15 minutes.

How has the Tiziana Life Sciences share price performed this year?

Shares in Tiziana Life Sciences are currently trading at 134p and the price has moved by 0.176k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Tiziana Life Sciences price has moved by 0.243k% over the past year.

What are the analyst and broker recommendations for Tiziana Life Sciences?

Of the analysts with advisory recommendations for Tiziana Life Sciences, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Tiziana Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Tiziana Life Sciences next release its financial results?

Tiziana Life Sciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Tiziana Life Sciences dividend yield?

Tiziana Life Sciences does not currently pay a dividend.

Does Tiziana Life Sciences pay a dividend?

Tiziana Life Sciences does not currently pay a dividend.

When does Tiziana Life Sciences next pay dividends?

Tiziana Life Sciences does not currently pay a dividend.

How do I buy Tiziana Life Sciences shares?

To buy shares in Tiziana Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Tiziana Life Sciences?

Shares in Tiziana Life Sciences are currently trading at 134p, giving the company a market capitalisation of £271.8m.

Where are Tiziana Life Sciences shares listed? Where are Tiziana Life Sciences shares listed?

Here are the trading details for Tiziana Life Sciences:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: TILS
What kind of share is Tiziana Life Sciences?

Based on an overall assessment of its quality, value and momentum, Tiziana Life Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Tiziana Life Sciences share price forecast 2020?

Shares in Tiziana Life Sciences are currently priced at 134p. At that level they are trading at 0.252% discount to the analyst consensus target price of 134.34.

Analysts covering Tiziana Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -0.06194 for the next financial year.

How can I tell whether the Tiziana Life Sciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tiziana Life Sciences. Over the past six months, the relative strength of its shares against the market has been 0.273k%. At the current price of 134p, shares in Tiziana Life Sciences are trading at 62.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Tiziana Life Sciences PE Ratio?

We were not able to find PE ratio data for Tiziana Life Sciences.

Who are the key directors of Tiziana Life Sciences?

Tiziana Life Sciences's management team is headed by:

Percy Lomax - NED
Shailubhai Kunwar - CEO
Gabriele Cerrone - CHM
P. Cooper - SEC
Willy Simon - NED
James Tripp - COO
Tiziano Lazzaretti - CFO
Leopoldo Zambeletti - NED
John Brancaccio - NED
Who are the major shareholders of Tiziana Life Sciences?

Here are the top five shareholders of Tiziana Life Sciences based on the size of their shareholding:

Planwise Group, Ltd. Corporation
Percentage owned: 33.26% (63.7m shares)
Old Mutual International Isle of Man Limited Insurance Company
Percentage owned: 21.01% (33.8m shares)
Empery Asset Management, L.P. Investment Advisor/Hedge Fund
Percentage owned: 5.3% (10.2m shares)
Silverman (Morris) Individual Investor
Percentage owned: 4.15% (7.94m shares)
Fonda (Laura) Individual Investor
Percentage owned: 3.88% (7.42m shares)
Similar to TILS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.